The Journal of Immunology, Vol 146, Issue 3 1020-1025, Copyright © 1991 by American Association of Immunologists

ARTICLES

Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites

Y Charoenvit, S Mellouk, C Cole, R Bechara, MF Leef, M Sedegah, LF Yuan, FA Robey, RL Beaudoin and SL Hoffman
Infectious Diseases Department, Naval Medical Research Institute, Bethesda, MD 20889-5055.

One of the primary strategies for malaria vaccine development has been to design subunit vaccines that induce protective levels of antibodies against the circumsporozoite (CS) protein of malaria sporozoites. In the Plasmodium yoelii mouse model system such vaccines have been uniformly unsuccessful in protecting against sporozoite-induced malaria. To demonstrate that antibodies to P. yoelii CS protein could provide protection we established a passive transfer model. Passive transfer of Navy yoelii sporozoite 1 (NYS1), an IgG3 mAb against the P. yoelii CS protein, protected 100% of mice against challenge with 5000 P. yoelii sporozoites. Binding of NYS1 to sporozoites was inhibited by incubation with (QGPGAP)2, a synthetic peptide derived from the repeat region of the P. yoelii CS protein, indicating that the epitope on sporozoites recognized by this mAb was included within this peptide. The levels of antibodies to (QGPGAP)2 by ELISA, and to sporozoites by indirect fluorescent antibody test and CS precipitation reaction were similar in sera from mice that received NYS1 in passive transfer and were protected against challenge with 5000 sporozoites, and from mice that had been immunized with subunit vaccines containing (QGPGAP)2 but were not protected against challenge with 40-200 sporozoites. To determine if antibody avidity, not absolute concentration could explain the striking differences in protection, we established a thiocyanate elution assay. The results suggest that NYS1, the protective mAb, has a lower avidity for (QGPGAP)2 and for sporozoites than do the vaccine- induced antibodies. Although the results of the conventional antibody assays did not correlate with protection, sera from the protected animals inhibited sporozoite development in mouse hepatocyte cultures significantly more than did the sera from the unprotected, subunit vaccine-immunized animals, correlating with protection. The data clearly demonstrate that antibodies to the CS protein can protect against intense sporozoite infection. Improved understanding of the differences between protective mAb and nonprotective polyclonal antibodies will be important in the further development of malaria vaccines.

This article has been cited by other articles:

				S. B. Boscardin, J. C.R. Hafalla, R. F. Masilamani, A. O. Kamphorst, H. A. Zebroski, U. Rai, A. Morrot, F. Zavala, R. M. Steinman, R. S. Nussenzweig, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses J. Exp. Med., March 20, 2006; 203(3): 599 - 606. [Abstract] [Full Text] [PDF]

				D. Haddad, E. Bilcikova, A. A. Witney, J. M. Carlton, C. E. White, P. L. Blair, R. Chattopadhyay, J. Russell, E. Abot, Y. Charoenvit, et al. Novel Antigen Identification Method for Discovery of Protective Malaria Antigens by Rapid Testing of DNA Vaccines Encoding Exons from the Parasite Genome Infect. Immun., March 1, 2004; 72(3): 1594 - 1602. [Abstract] [Full Text] [PDF]

				R. Chattopadhyay, D. Rathore, H. Fujioka, S. Kumar, P. de la Vega, D. Haynes, K. Moch, D. Fryauff, R. Wang, D. J. Carucci, et al. PfSPATR, a Plasmodium falciparum Protein Containing an Altered Thrombospondin Type I Repeat Domain Is Expressed at Several Stages of the Parasite Life Cycle and Is the Target of Inhibitory Antibodies J. Biol. Chem., July 3, 2003; 278(28): 25977 - 25981. [Abstract] [Full Text] [PDF]

				M. Sedegah, G. T. Brice, W. O. Rogers, D. L. Doolan, Y. Charoenvit, T. R. Jones, V. F. Majam, A. Belmonte, M. Lu, M. Belmonte, et al. Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations Infect. Immun., July 1, 2002; 70(7): 3493 - 3499. [Abstract] [Full Text] [PDF]

				K. Brahimi, E. Badell, J.-P. Sauzet, L. BenMohamed, P. Daubersies, C. Guerin-Marchand, G. Snounou, and P. Druilhe Human Antibodies against Plasmodium falciparum Liver-Stage Antigen 3 Cross-React with Plasmodium yoelii Preerythrocytic-Stage Epitopes and Inhibit Sporozoite Invasion In Vitro and In Vivo Infect. Immun., June 1, 2001; 69(6): 3845 - 3852. [Abstract] [Full Text] [PDF]

				G. I. Sanchez, M. Sedegah, W. O. Rogers, T. R. Jones, J. Sacci, A. Witney, D. J. Carucci, N. Kumar, and S. L. Hoffman Immunogenicity and Protective Efficacy of a Plasmodium yoelii Hsp60 DNA Vaccine in BALB/c Mice Infect. Immun., June 1, 2001; 69(6): 3897 - 3905. [Abstract] [Full Text] [PDF]

				D. Haddad, J. Ramprakash, M. Sedegah, Y. Charoenvit, R. Baumgartner, S. Kumar, S. L. Hoffman, and W. R. Weiss Plasmid Vaccine Expressing Granulocyte-Macrophage Colony-Stimulating Factor Attracts Infiltrates Including Immature Dendritic Cells into Injected Muscles J. Immunol., October 1, 2000; 165(7): 3772 - 3781. [Abstract] [Full Text] [PDF]

				H. Charest, M. Sedegah, G. S. Yap, R. T. Gazzinelli, P. Caspar, S. L. Hoffman, and A. Sher Recombinant Attenuated Toxoplasma gondii Expressing the Plasmodium yoelii Circumsporozoite Protein Provides Highly Effective Priming for CD8+ T Cell-Dependent Protective Immunity Against Malaria J. Immunol., August 15, 2000; 165(4): 2084 - 2092. [Abstract] [Full Text] [PDF]

				D. L. Doolan, S. Southwood, R. Chesnut, E. Appella, E. Gomez, A. Richards, Y. I. Higashimoto, A. Maewal, J. Sidney, R. A. Gramzinski, et al. HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles J. Immunol., July 15, 2000; 165(2): 1123 - 1137. [Abstract] [Full Text] [PDF]

				M. Sedegah, W. Weiss, J. B. Sacci Jr., Y. Charoenvit, R. Hedstrom, K. Gowda, V. F. Majam, J. Tine, S. Kumar, P. Hobart, et al. Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus J. Immunol., June 1, 2000; 164(11): 5905 - 5912. [Abstract] [Full Text] [PDF]

				Y. Charoenvit, V. F. Majam, G. Corradin, J. B. Sacci Jr., R. Wang, D. L. Doolan, T. R. Jones, E. Abot, M. E. Patarroyo, F. Guzman, et al. CD4+ T-Cell- and Gamma Interferon-Dependent Protection against Murine Malaria by Immunization with Linear Synthetic Peptides from a Plasmodium yoelii 17-Kilodalton Hepatocyte Erythrocyte Protein Infect. Immun., November 1, 1999; 67(11): 5604 - 5614. [Abstract] [Full Text] [PDF]

				C. A. Lobo, R. Dhar, and N. Kumar Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking Antibodies Infect. Immun., April 1, 1999; 67(4): 1688 - 1693. [Abstract] [Full Text] [PDF]

				M. Ichino, G. Mor, J. Conover, W. R. Weiss, M. Takeno, K. J. Ishii, and D. M. Klinman Factors Associated with the Development of Neonatal Tolerance After the Administration of a Plasmid DNA Vaccine J. Immunol., April 1, 1999; 162(7): 3814 - 3818. [Abstract] [Full Text] [PDF]

				W. R. Weiss, K. J. Ishii, R. C. Hedstrom, M. Sedegah, M. Ichino, K. Barnhart, D. M. Klinman, and S. L. Hoffman A Plasmid Encoding Murine Granulocyte-Macrophage Colony-Stimulating Factor Increases Protection Conferred by a Malaria DNA Vaccine J. Immunol., September 1, 1998; 161(5): 2325 - 2332. [Abstract] [Full Text] [PDF]

				S Khusmith, Y Charoenvit, S Kumar, M Sedegah, R. Beaudoin, and S. Hoffman Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein Science, May 3, 1991; 252(5006): 715 - 718. [Abstract] [PDF]